How Leqembi and Kisunla Fight Alzheimer's in Different Ways
A diagnosis of Alzheimer's no longer means there are no treatment options. Two FDA-approved drugs, Leqembi and Kisunla, can slow the disease for people diagnosed early, but they work differently. Understanding how beta-amyloid changes from harmless protein fragments into toxic oligomers, protofibrils, plaques, and eventually tau tangles can help patients and families make more informed treatment decisions.
Medicare Advantage Isn't Always an Advantage for Alzheimer's
Choosing the right Medicare coverage can have a major impact on Alzheimer's treatment. While Medicare Advantage plans often offer lower premiums and extra benefits, they may also require prior authorizations, network restrictions, and additional approvals that can delay time-sensitive therapies such as Leqembi and Kisunla. Learn why many Alzheimer's specialists recommend Original Medicare with a Medigap supplement for patients who need access to advanced neurological care.